SPAC30D11.01c Antibody

What is SPAC30D11.01c and what organism does it originate from?

SPAC30D11.01c is a protein found in Schizosaccharomyces pombe (strain 972 / ATCC 24843), commonly known as fission yeast . This protein appears to be functionally related to alpha-glucosidase (AGLU) based on antibody cross-reactivity studies . The protein has been assigned the UniProt accession number Q09901, which serves as its unique identifier in protein databases . Understanding the origin and classification of this protein is essential for designing appropriate experimental controls and interpreting results in a species-specific context.

What applications are SPAC30D11.01c antibodies validated for?

SPAC30D11.01c antibodies have been tested and validated for several common laboratory applications:

• Enzyme-Linked Immunosorbent Assay (ELISA): For quantitative protein detection in solution

• Western Blot (WB): For identification of the target protein in complex mixtures

These antibodies are specifically developed for research applications and are not intended for diagnostic or therapeutic procedures . When designing experiments, researchers should consider that the antibodies have been validated specifically for these applications, and use in other techniques may require additional optimization and validation steps.

What are the recommended storage conditions for SPAC30D11.01c antibodies?

Proper storage is critical for maintaining antibody functionality. For SPAC30D11.01c antibodies:

• Store at -20°C or -80°C upon receipt

• Avoid repeated freeze-thaw cycles which can damage antibody structure and function

• The antibodies are typically provided in a liquid form containing preservatives and stabilizers

The specific storage buffer composition includes:

• Preservative: 0.03% Proclin 300

• Constituents: 50% Glycerol, 0.01M PBS, pH 7.4

This buffer formulation helps maintain antibody stability during storage and prevents microbial contamination.

What is the difference between polyclonal and monoclonal antibodies against SPAC30D11.01c?

The commercially available SPAC30D11.01c antibodies are primarily polyclonal antibodies raised in rabbits . Understanding the distinction between polyclonal and monoclonal antibodies is important:

The polyclonal nature of available SPAC30D11.01c antibodies means they can recognize multiple epitopes on the target protein, potentially increasing detection sensitivity but requiring careful validation for specificity.

How can I validate the specificity of a SPAC30D11.01c antibody for my experiments?

Validating antibody specificity is crucial for generating reliable research data. For SPAC30D11.01c antibodies, consider these methodological approaches:

• Positive Controls: Use purified recombinant SPAC30D11.01c protein or lysates from wild-type S. pombe (strain 972) .

• Negative Controls:

  • S. pombe strains with SPAC30D11.01c gene deletion

  • Lysates from organisms lacking homologous proteins

  • Blocking experiments with immunizing peptides

• Specificity Tests:

  • Western blot analysis should show a single band at the expected molecular weight

  • Immunoprecipitation followed by mass spectrometry to confirm target identity

  • Comparison with alternative antibodies against the same target if available

• Cross-reactivity Assessment: Test the antibody against proteins with similar sequences or structural domains that might be recognized by the antibody .

Remember that the antibody has been purified using antigen affinity methods, which increases specificity but does not guarantee complete absence of cross-reactivity .

What are the best practices for optimizing Western blot protocols with SPAC30D11.01c antibodies?

When working with SPAC30D11.01c antibodies in Western blot applications, consider these methodological optimizations:

• Sample Preparation:

  • For yeast samples, use glass bead lysis under denaturing conditions to ensure complete protein extraction

  • Include protease inhibitors to prevent degradation of the target protein

  • Standardize protein quantification methods across samples

• Antibody Titration:

  • Begin with a concentration range of 1:500 to 1:2000 dilution

  • Perform a dilution series to determine optimal signal-to-noise ratio

  • Consider extended incubation times (overnight at 4°C) for weaker signals

• Blocking Optimization:

  • Test different blocking agents (BSA vs. non-fat dry milk)

  • Optimize blocking time and temperature

  • Consider including 0.1-0.3% Tween-20 in blocking and washing buffers

• Detection Considerations:

  • For low abundance proteins, consider using more sensitive detection methods such as enhanced chemiluminescence (ECL) or fluorescence-based detection

  • Longer exposure times may be necessary depending on protein expression levels

• Controls:

  • Include loading controls appropriate for yeast studies (e.g., Cdc2, actin)

  • If possible, include samples from SPAC30D11.01c knockout strains as negative controls

Following these optimization steps systematically will help achieve reliable and reproducible Western blot results with SPAC30D11.01c antibodies.

How do I troubleshoot inconsistent results when using SPAC30D11.01c antibodies in immunoassays?

When facing inconsistent results with SPAC30D11.01c antibodies, a systematic troubleshooting approach is essential:

• Antibody Quality Assessment:

  • Check antibody expiration date and storage conditions

  • Avoid repeated freeze-thaw cycles that could compromise antibody activity

  • Consider aliquoting antibodies to minimize freeze-thaw events

• Sample Preparation Issues:

  • Ensure consistent protein extraction methods across experiments

  • Verify protein integrity by Coomassie staining or Ponceau S staining

  • Consider yeast-specific extraction challenges (cell wall components, post-translational modifications)

• Protocol Standardization:

  • Document and standardize all protocol steps

  • Control temperature and timing precisely

  • Use calibrated pipettes and fresh reagents

• Technical Variations:

  • If using ELISA, prepare standard curves for each experiment

  • For Western blotting, ensure consistent transfer efficiency

  • Document lot numbers of all reagents used

• Specificity Issues:

  • Re-validate antibody specificity if inconsistencies appear

  • Consider epitope masking due to protein-protein interactions or conformational changes

  • Test different protein denaturation conditions if epitope accessibility is a concern

• Biological Variations:

  • Control for growth phase of yeast cultures

  • Consider cell cycle-dependent protein expression

  • Standardize environmental conditions for yeast growth

Creating a detailed troubleshooting log that tracks all experimental variables can help identify the source of inconsistencies.

What experimental design considerations are important when studying post-translational modifications of SPAC30D11.01c?

When investigating post-translational modifications (PTMs) of SPAC30D11.01c, consider these methodological approaches:

• Antibody Selection:

  • Standard SPAC30D11.01c antibodies may recognize the protein regardless of certain PTMs

  • For specific PTM detection, consider developing or sourcing PTM-specific antibodies

  • Verify whether the existing antibody's epitope includes potential PTM sites

• Sample Preparation:

  • Include phosphatase inhibitors when studying phosphorylation

  • For ubiquitination studies, include deubiquitinating enzyme inhibitors

  • Consider native versus denaturing conditions depending on the PTM of interest

• Analytical Approaches:

  • Use Phos-tag™ gels for phosphorylation studies

  • Consider 2D gel electrophoresis to separate different protein isoforms

  • Implement immunoprecipitation followed by mass spectrometry for PTM identification

• Confirmatory Techniques:

  • Site-directed mutagenesis of putative modification sites

  • In vitro enzymatic assays to confirm modification capabilities

  • Compare wild-type to mutant phenotypes lacking specific PTM sites

• Experimental Controls:

  • Include samples treated with specific modifying or demodifying enzymes

  • Use inhibitors of specific PTM pathways to confirm specificity

  • Compare conditions known to induce or suppress specific modifications

Understanding the biological context in which these modifications occur is essential for designing appropriate experimental conditions to capture the relevant PTM states of SPAC30D11.01c.

What controls should be included when using SPAC30D11.01c antibodies in yeast studies?

Proper experimental controls are critical for generating reliable data with SPAC30D11.01c antibodies:

• Positive Controls:

  • Wild-type S. pombe (strain 972 / ATCC 24843) expressing endogenous SPAC30D11.01c

  • Recombinant SPAC30D11.01c protein (can serve as a size reference)

  • Overexpression strains with tagged SPAC30D11.01c

• Negative Controls:

  • SPAC30D11.01c deletion strains

  • Non-target yeast species lacking close homologs

  • Primary antibody omission control

  • Isotype control (rabbit IgG matched to antibody concentration)

• Experimental Controls:

  • Housekeeping protein detection (e.g., actin, tubulin) to normalize loading

  • Subcellular fraction markers when performing localization studies

  • Time course controls if studying dynamic processes

  • Environmental condition controls (temperature, media composition)

• Technical Controls:

  • Blocking peptide competition assays to confirm specificity

  • Secondary antibody-only controls to assess non-specific binding

  • Multiple antibody lots if available to confirm consistency

Implementing these controls systematically will help distinguish genuine biological signals from technical artifacts and increase confidence in experimental results.

How can I optimize ELISA protocols for detecting SPAC30D11.01c in complex samples?

ELISA optimization for SPAC30D11.01c detection requires attention to several methodological details:

• Antibody Concentration Optimization:

  • Perform checkerboard titration of primary and secondary antibodies

  • Typical starting dilutions range from 1:100 to 1:5000

  • Optimize for signal-to-noise ratio, not just signal strength

• Sample Preparation:

  • For yeast lysates, test different lysis methods (mechanical, enzymatic, detergent-based)

  • Determine optimal protein concentration range (typically 0.1-10 μg/ml for total protein)

  • Consider sample pre-clearing steps to reduce background

• Protocol Refinement:

  • Test different blocking agents (BSA, casein, commercial blockers)

  • Optimize incubation times and temperatures

  • Evaluate washing stringency (buffer composition, number of washes)

• Standard Curve Development:

  • Use purified recombinant SPAC30D11.01c protein for standard curve

  • Ensure standard curve covers expected concentration range

  • Verify linearity within the working range

• Data Analysis:

  • Use appropriate curve-fitting methods (4-parameter logistic for sandwich ELISA)

  • Establish lower limit of detection and quantification

  • Implement statistical methods to assess precision and accuracy

• Specificity Enhancements:

  • For sandwich ELISA, use antibodies recognizing different epitopes

  • Consider capture antibody orientation and density optimization

  • Test sample dilution linearity to confirm absence of matrix effects

Following these optimization steps will help develop a robust ELISA protocol for specific and sensitive detection of SPAC30D11.01c in complex biological samples.

What approaches can be used to study SPAC30D11.01c protein-protein interactions?

Several methodologies can be employed to investigate SPAC30D11.01c protein interactions:

• Co-Immunoprecipitation (Co-IP):

  • Use SPAC30D11.01c antibodies for immunoprecipitation

  • Optimize lysis conditions to preserve protein complexes

  • Consider crosslinking approaches for transient interactions

  • Analyze precipitated complexes by mass spectrometry or Western blot

• Proximity Labeling:

  • Express SPAC30D11.01c fused to BioID or APEX2

  • Perform biotin labeling followed by streptavidin pulldown

  • Identify neighboring proteins by mass spectrometry

  • Validate interactions using SPAC30D11.01c antibodies

• Yeast Two-Hybrid (Y2H):

  • Use SPAC30D11.01c as bait to screen for interacting partners

  • Confirm interactions by reciprocal Y2H

  • Validate interactions with co-IP using SPAC30D11.01c antibodies

• Fluorescence Microscopy:

  • Perform co-localization studies with fluorescently tagged potential partners

  • Use SPAC30D11.01c antibodies for immunofluorescence if tags affect function

  • Consider advanced techniques like FRET or FLIM to confirm direct interactions

• Crosslinking Mass Spectrometry (XL-MS):

  • Crosslink protein complexes in vivo or in vitro

  • Enrich SPAC30D11.01c using specific antibodies

  • Identify crosslinked peptides by mass spectrometry

  • Generate structural models of protein-protein interfaces

These approaches provide complementary information and should be used in combination for comprehensive interaction characterization.

How can computational approaches complement antibody-based studies of SPAC30D11.01c?

Computational methods can significantly enhance experimental studies using SPAC30D11.01c antibodies:

• Structural Prediction and Analysis:

  • Generate protein structure models using AlphaFold or similar tools

  • Identify potential antibody epitopes computationally

  • Predict functional domains and interaction sites

  • Guide experimental design for epitope mapping or functional studies

• Sequence Analysis:

  • Perform multiple sequence alignments to identify conserved regions

  • Predict post-translational modification sites

  • Identify orthologs in other species for comparative studies

  • Assess epitope conservation across species for cross-reactivity prediction

• Network Analysis:

  • Integrate experimental protein-protein interaction data into interaction networks

  • Identify functional clusters and potential pathways

  • Predict additional interaction partners

  • Generate testable hypotheses for antibody-based validation

• Data Mining:

  • Search public repositories for transcriptomic and proteomic data featuring SPAC30D11.01c

  • Identify conditions affecting expression or modification

  • Extract information about potential functions from large datasets

  • Guide experimental design based on expression patterns

• In Silico Antibody Design:

  • Use computational protocols like IsAb for antibody design

  • Predict antibody-antigen binding using docking algorithms

  • Identify potential improved epitopes for new antibody development

  • Model antibody-antigen complexes to understand binding mechanisms

Using computational approaches alongside experimental techniques can accelerate research, generate new hypotheses, and provide context for interpreting antibody-based experimental results.

How do I address potential cross-reactivity issues with SPAC30D11.01c antibodies?

Cross-reactivity is a common challenge with antibodies, particularly polyclonal antibodies. Here's a methodical approach to address this issue:

• Cross-Reactivity Assessment:

  • Test the antibody in organisms lacking SPAC30D11.01c

  • Compare banding patterns in wild-type versus knockout samples

  • Consider testing against recombinant proteins with similar domains

  • Perform bioinformatic analysis to identify proteins with similar epitopes

• Specificity Enhancement:

  • Use antigen pre-absorption to remove cross-reactive antibodies

  • Consider affinity purification against the specific target

  • Optimize antibody concentration to minimize non-specific binding

  • Increase washing stringency in immunoassay protocols

• Validation Approaches:

  • Use orthogonal detection methods (e.g., mass spectrometry)

  • Confirm results with alternative antibodies if available

  • Employ genetic approaches (knockdown, knockout) to validate specificity

  • Use tagged versions of the protein as controls

• Data Interpretation:

  • Document potential cross-reactive species in your experimental system

  • Consider molecular weight and expression pattern differences

  • Be transparent about potential limitations in publications

  • Perform additional controls when cross-reactivity cannot be eliminated

Although SPAC30D11.01c antibodies are purified by antigen affinity methods , some degree of cross-reactivity may still occur, particularly with closely related proteins or when used in non-yeast systems.

What methods can be used to determine the optimal concentration of SPAC30D11.01c antibodies for different applications?

Determining optimal antibody concentration is critical for balancing sensitivity and specificity:

• Western Blot Titration:

  • Prepare a dilution series (e.g., 1:500, 1:1000, 1:2000, 1:5000)

  • Use consistent sample amounts across all conditions

  • Evaluate signal-to-noise ratio at each concentration

  • Select the dilution that provides clear signal with minimal background

• ELISA Optimization:

  • Perform checkerboard titration with varying antibody and antigen concentrations

  • Calculate signal-to-noise ratios for each combination

  • Determine lower limit of detection at each antibody concentration

  • Select concentration based on required assay sensitivity and dynamic range

• Immunofluorescence Optimization:

  • Test antibody dilutions ranging from 1:50 to 1:1000

  • Include negative controls at each concentration

  • Evaluate specificity of subcellular localization pattern

  • Select dilution that maximizes specific signal while minimizing background

• Systematic Approach:

  • Start with manufacturer's recommended range

  • Test at least 3-4 different concentrations

  • Document all optimization steps for reproducibility

  • Re-optimize when changing sample types or detection systems

• Quality Control Measures:

  • Include positive and negative controls at the selected concentration

  • Periodically revalidate optimal concentration with new antibody lots

  • Monitor signal consistency across experiments

  • Adjust concentration if necessary based on experimental conditions

Creating a standardized optimization protocol for each application will ensure consistent results across experiments and maximize the utility of SPAC30D11.01c antibodies.